145 East 32nd Street
New York, NY 10016
Dr. Galvin's lab focuses on (1) developing new biomarkers of neurodegenerative disease; (2) early detection of cognitive impairment through culturally sensitive methods; and (3) translating these findings to the community at large by improving knowledge. Currently, there are 7 studies funded as part of this lab:
* Multicultural Community Dementia Screening
The major goals of this project are to provide cross-cultural validation of dementia screening methods and biological validation against imaging and CSF biomarkers of Alzheimer disease and related disorders.
* Alzheimer's Disease Assistance Center
The major goals of this project is to provide clinical services for underserved communities and increase physician awareness of brain aging and dementia related topics.
* Bioantomical Correlates of Cognitive Phenotypes in PD, PC-MCI, and PDD
The major goals of this project define the Mild Cognitive Impairment stage of PD and map out the functional connectome of PD using structural and functional MRI and high density EEG.
* Biomarker Studies of Risk Factors for Cognitive Disorders in Older Adults
The major goals of this project are to screen multicultural communities for common medical illness to determine future risk of dementia and validate with FDG-PET.
* Piloting an Early Intervention Fall Prevention Program for Community-Dwelling Elderly with Dementia
The major goals of this project are to adapt a falls prevention program (C-PROFET) to reduce falls in vulnerable populations.
* Alzheimer's Disease Neuroimaging Initiative
The major goal of this project is to explore MRI, PET and CSF biomarkers that predict diagnosis of Alzheimer disease and conversion from health brain aging to cognitive impairment.
* New York University Family-Focused Aging Interdisciplinary Research Project
The major goal of this project is to test the feasibility and utility of Family Centered Function Focused Care (FC-FFC), a system-level intervention to improve patient- and family-centered health outcomes.
These studies are funded by NIH, Michael J. Fox Foundation, New York State Department of Health, Alzheimer Association, and the Alma and Morris Schapiro Foundation.
Dr. Galvin plans to initiate additional studies that support the goal of his lab.
Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): A qualitative analysis of clinical studies in patients with Alzheimer's disease
Alva, G; Cummings, JL; Galvin, JE; Meng, X; Velting, DM
2015-04-01; 1368-5031,International journal of clinical practice - id: 1515742, year: 2015
Whipple's Disease Masquerades as Dementia With Lewy Bodies
Hurth, Kyle; Tarawneh, Rawan; Ghoshal, Nupur; Benzinger, Tammie L S; Clifford, David B; Geschwind, Michael; Morris, John C; Galvin, James E; Schmidt, Robert E; Cairns, Nigel J
2015-02-23; 0893-0341,Alzheimer disease & associated disorders - id: 1466382, year: 2015 Journal Article
Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch
Molinuevo, Jose L; Frolich, Lutz; Grossberg, George T; Galvin, James E; Cummings, Jeffrey L; Krahnke, Tillmann; Strohmaier, Christine
2015-03-16; 1758-9193,Alzheimer's research & therapy - id: 1495832, year: 2015 Journal Article
Sarcopenia and impairment in cognitive and physical performance
Tolea, Magdalena I; Galvin, James E
2015-04-20; 1178-1998,Clinical interventions in aging - id: 1532262, year: 2015 Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Testing a family-centered intervention to promote functional and cognitive recovery in hospitalized older adults
Boltz, Marie; Resnick, Barbara; Chippendale, Tracy; Galvin, James
2015-02-03; 0002-8614,Journal of the American Geriatrics Society - id: 1449192, year: 2014 Journal Article